Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease
Open Access
- 12 May 2026
- journal article
- review article
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 41 (7) , 2006-2029
Abstract
Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab, risankizumab) are the newest advanced therapies in our armamentarium for the treatment of IBD. The aim of the Asia‐Pacific consensus statements is to provide context‐specific recommendations integrating real‐world evidence specific to our region. The Asian‐Pacific Association of Gastroenterology (APAGE) Committee on Inflammatory Bowel Disease, with the participation of Asian Education Network in Inflammatory Bowel Disease (AEN‐IBD), convened a forum of 34 IBD experts from 12 countries to develop consensus guidelines on the best practices on the use of these new advanced therapies using the modified Delphi method. IL‐23 p19 inhibitors have shown good efficacy in biologic‐naïve and experienced patients in both UC and CD, with clinical and endoscopic superiority over ustekinumab and an excellent safety profile. JAK inhibitors (tofacitinib and filgotinib) are efficacious in UC, and upadacitinib is efficacious in both UC and CD. They have a rapid time to response, and emerging data on acute severe UC appears promising. However, careful screening and monitoring is needed for known side effects, and prophylactic vaccination for herpes zoster should be considered. S1P modulators (ozanimod, etrasimod) are efficacious in UC with a favorable side effect profile.Keywords
Funding Information
- Journal of Gastroenterology and Hepatology Foundation
- Ferring
This publication has 121 references indexed in Scilit:
- Induction Efficacy and Safety of Upadacitinib for Active Crohn's Disease in Japanese Patients: A Multicenter Retrospective StudyJGH Open, 2025
- Real‐World Comparative Effectiveness and Safety of Filgotinib and Upadacitinib for Ulcerative Colitis: A Multicentre Cohort StudyUnited European Gastroenterology Journal, 2024
- Risankizumab for Ulcerative ColitisJAMA, 2024
- Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2Dermatology and Therapy, 2023
- UEG Week 2022 Oral PresentationsUnited European Gastroenterology Journal, 2022
- Efficacy of Recombinant Zoster Vaccine in Patients With Inflammatory Bowel DiseaseClinical Gastroenterology and Hepatology, 2022
- Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune‐mediated inflammatory diseases: A European retrospective observational studyUnited European Gastroenterology Journal, 2021
- Tofacitinib for Biologic-Experienced Hospitalized Patients With Acute Severe Ulcerative Colitis: A Retrospective Case-Control StudyClinical Gastroenterology and Hepatology, 2021
- Tofacitinib Induction Therapy Reduces Symptoms Within 3 Days for Patients With Ulcerative ColitisClinical Gastroenterology and Hepatology, 2019
- Safety and tolerability of concurrent natalizumab treatment for patients with Crohnʼs disease not in remission while receiving infliximabInflammatory Bowel Diseases, 2007